Oncology and Hematology

Episodes 33-48 of 530

Stories in PNH: Case Experiences from the Clinic
Stories in PNH: Case Experiences from the Clinic
Project Oncology®
Stories in PNH: Case Experiences from the Clinic
- Charles Turck, PharmD, BCPS, BCCCP
- Timothy Kubal, MD
Next-Generation Horizons in PNH Therapies
Next-Generation Horizons in PNH Therapies
Project Oncology®
Next-Generation Horizons in PNH Therapies
- Vinod Pullarkat, MD
Managing PNH: Clinical Considerations
Managing PNH: Clinical Considerations
Project Oncology®
Managing PNH: Clinical Considerations
- Charles Turck, PharmD, BCPS, BCCCP
- Jamie Koprivnikar, MD
- Abdulraheem Yacoub, MD
Understanding the Role of the Alternate Complement Pathway in PNH
Understanding the Role of the Alternate Complement Pathway in PNH
Project Oncology®
Understanding the Role of the Alternate Complement Pathway in PNH
- Jennifer Caudle, DO
- Catherine Broome, MD
Recognizing the Burden of Paroxysmal Nocturnal Hemoglobinuria
Recognizing the Burden of Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®
Recognizing the Burden of Paroxysmal Nocturnal Hemoglobinuria
- Brian P. McDonough, MD, FAAFP
Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®
Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
- Brian P. McDonough, MD, FAAFP
Conquering the Burden & Impacts of PNH
Conquering the Burden & Impacts of PNH
Project Oncology®
Conquering the Burden & Impacts of PNH
- Charles Turck, PharmD, BCPS, BCCCP
- Hana Safah, MD
- Timothy Kubal, MD
Improving PNH Patient Outcomes
Improving PNH Patient Outcomes
Project Oncology®
Improving PNH Patient Outcomes
- Charles Turck, PharmD, BCPS, BCCCP
- David Dingli, MD, PhD
Examining the Treatment Paradigm for Paroxysmal Nocturnal Hemoglobinuria
Examining the Treatment Paradigm for Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®
Examining the Treatment Paradigm for Paroxysmal Nocturnal Hemoglobinuria
- Charles Turck, PharmD, BCPS, BCCCP
- Brian Mulherin, MD
Managing PNH Patients: Addressing the Unmet Needs
Managing PNH Patients: Addressing the Unmet Needs
Project Oncology®
Managing PNH Patients: Addressing the Unmet Needs
- Charles Turck, PharmD, BCPS, BCCCP
- Brian Mulherin, MD
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart Matters
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
- Jun-ichi Abe, MD, PhD
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Project Oncology®
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
- Ryan Quigley
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Project Oncology®
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Project Oncology®
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Project Oncology®
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape